Pravastatin--ocular side effects after a two year follow-up?
Pravastatin, a new HMG-CoA-reductase inhibitor, was administered to hypercholesterolemic 14 patients with coronary heart disease for a period of two years. This drug reduces the plasma LDL-cholesterol concentrations approximately 30-40%. No development of cataracts or other ocular side effects could be observed during this two year follow-up.
Behrens-Baumann
W
W
Department of Ophthalmology, University of Goettingen, FRG.
Thiery
J
J
Fieseler
H G
HG
Seidel
D
D
D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002386:Cataract / Q000139:chemically induced*; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006538:Heptanoic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D007908:Lens, Crystalline / Q000187:drug effects*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000009:adverse effects* / Q000627:therapeutic use; D017035:Pravastatin; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D009281:Naphthalenes; D014280:Triglycerides; D017035:Pravastatin